.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,556,978

« Back to Dashboard

Details for Patent: 5,556,978

Title: Neuromuscular blocking agents
Abstract:1R-cis, 1'R-cis isomer of a 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl-1-veratrylisoquinolinium) salt, substantially free from other geometrical and optical isomers thereof. The 1R-cis,1'R-cis isomer has been found to have an advantageous combination of pharmacological properties, notably greater neuromuscular blocking potency, weaker histamine-releasing potency, and at equivalent levels of neuromuscular blockade, fewer potential adverse effects on the autonomic nervous system (sympathetic and parasympathetic blockade), in comparison with the known mixture of geometrical and optical isomers.
Inventor(s): Hill; Derek A. (Dartford, GB2), Turner; Geoffrey L. (Dartford, GB2)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Filing Date:Mar 28, 1995
Application Number:08/413,217
Claims:1. A process for the preparation of 1R-cis, 1'R-cis 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl veratrylisoqinolinium) in the form of a salt having a physiologically acceptable anion selected from halide, sulphate, phosphate, acetate, propionate, succinate, maleate, mesylate, besylate, tosylate or napthalenesulphonate; in admixture with less than 8% w/w of other geometrical and optical isomers thereof, which process comprises subjecting a 1R,1'R 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl veratrylisoquinolinium salt having the required anion to high performance liquid chromatography using a silica stationary phase and a non-aqueous mobile phase in the presence of a strong acid.

2. A process according to claim 1 for the preparation of 1R-cis 1'R-cis 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl veratrylisoquinolinium) in the form of a salt having a physiologically acceptable anion selected from halide, sulphate, phosphate, acetate, propionate, succinate, maleate, mesylate, besylate, tosylate or napthalenesulphonate; in admixture with less than 5% of other geometrical and optical isomers thereof.

3. A process according to claim 1 for the preparation of 1R-cis 1'R-cis 1'R-cis 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl veratrylisoquinolinium) in the form of a salt having a physiologically acceptable anion selected from halide, sulphate, phosphate, acetate, propionate, succinate, maleate, mesylate, besylate, tosylate or naphthalenesulphonate; in admixture with less than 2% of other geometrical and optical isomers thereof.

4. A process according to claim 1 wherein the non-aqueous mobile phase comprises a mixture of solvents.

5. A process according to claim 4 wherein said mixture comprises a chlorinated hydrocarbon and an alcohol.

6. A process according to claim 5 wherein said chlorinated hydrocarbon is methylene chloride.

7. A process according to claim 5 wherein said alcohol is methanol.

8. A process according to any of claims 1 to 7 wherein said strong acid is selected from benzenesulphonic acid, methanesulphonic acid, p-toluenesulphonic acid or phosphoric acid.

9. A process for the preparation of 1R-cis, 1'R-cis 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl veratrylisoquinolinium mesylate) in admixture with less than 8% w/w of other geometrical and optical isomers thereof which process comprises subjecting a 1R,1'R atracurium mesylate salt to high performance liquid chromatography using a silica stationary phase and a non-aqueous mobile phase, said mobile phase comprising a mixture of methylene chloride and methanol, in the presence of methanesulphonic acid.

10. A process according to claim 9 for the preparation of 1R-cis,1'R-cis 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl veratrylisoquinolinium mesylate) in a mixture with less than 5% w/w of other geometrical and optical isomers thereof.

11. A process according to claim 9 for the preparation of 1R-cis,1'R-cis 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl veratrylisoquinolinium mesylate) in admixture with less than 2% w/w of other geometrical and optical isomers thereof.

12. A process according to any of claims 1 to 11 wherein the ratio of methylene chloride:methanol:methanesulphonic acid is 80:20:05.

13. A process for the preparation of 1R-cis,1'R-cis 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl veratrylisoquinolinium besylate) in admixture with less than 8% w/w of other geometrical and optical isomers thereof which process comprises subjecting a 1R,1'R besylate salt to high performance liquid chromatography using a silica stationary phase and a non-aqueous mobile phase, said mobile phase comprising a mixture of methylene chloride and methanol, in the presence of benzenesulphonic acid.

14. A process according to any of claims 1 to 11 wherein the ratio of methylene chloride:methanol:benzenesulphonic acid is 4000:500:0.25.

15. A process for the preparation of 1R-cis,1'R-cis 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl veratrylisoquinolinium besylate) in admixture with less than 8% w/w of other geometrical and optical isomers thereof which process comprises subjecting a 1R,1'R 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl-veratrylisoquinolinium besylate) to high performance liquid chromatography using a silica stationary phase and a non-aqueous mobile phase, said mobile phase comprising a mixture of methylene chloride and methanol, in the presence of benzenesulphonic acid followed by the additional steps of:

a) washing to remove solvents and excess acid; and

b) evaporation of the methylene chloride to give isolated 1R-cis,1'R cis 2',2'-(3,11-dioxo-4,10,-dioxatridecylene)-veratrylisoquinolinium besylate).

16. A process for the preparation of 1R-cis,1'R-cis 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl veratrylisoquinolinium besylate in solid form which comprises subjecting a 1R,1'R 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl veratrylisoquinolinium besylate) to high performance liquid chromatography using a silica stationary phase and a non-aqueous mobile phase, said mobile phase comprising a mixture of methylene chloride and methanol, in the presence of benzenesulphonic acid followed by the additional steps of:

a) washing to remove solvents and excess acid; and

b) evaporation of the methylene chloride to give isolated 1R-cis,1'R cis 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl veratrylisoquinolinium besylate);

c) dissolving the isolated 1R cis, 1'R cis 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl veratrylisoquinolinium besylate) in water;

d) adjusting the pH to approximately 3.5 to 4 using benzenesulphonic acid; and

e) lyophilisation.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc